August 15, 2025

Nivolumab Added to Chemoradiotherapy Reduced Recurrence Risk in High-Risk Head and Neck Cancer

Adding the PD-1 inhibitor nivolumab to standard chemoradiotherapy after surgery significantly reduced recurrence rates for patients with locally advanced head and neck squamous cell carcinoma who are ...

The ASCO Post

August 15, 2025

Upfront Radical Cytoreductive Surgery Extends Progression-Free Survival in Advanced Ovarian Cancer

The TRUST trial is the first phase III randomized study to show improved progression-free survival for primary cytoreductive surgery compared with interval surgery without compromising short-term or l...

The ASCO Post

August 14, 2025

Why Sarcomas Require Expert, Multidisciplinary Cancer Care

Sarcomas are one of the rarest and most complex cancer types, making up less than 1% of all new cancer diagnoses in the United States.

Baptist Health South Florida

August 07, 2025

Laser-Induced Polymer Fragmentation in IOLs

Even with the finest skills, technique, devices and experience, performance suffers when clarity is compromised

The Ophthalmologist

August 06, 2025

SCHWIND PresbyMAX: A Universe of Possibilities

Enhancing outcomes in presbyopic laser vision correction

The Ophthalmologist

July 23, 2025

IDSA Issues Stratified Antibiotic Approach for complicated UTIs

New recommendations outline a stratified antibiotic treatment for complicated urinary tract infections, including shorter durations, oral transition timing, and tailored empiric choices based on illness severity and resistance risks.

Conexiant

July 22, 2025

Adjuvant Use of Atezolizumab Plus Chemotherapy in DNA Mismatch Repair–Deficient Colon Cancer

For the adjuvant treatment of stage III colon cancer with DNA mismatch repair–deficient (dMMR) tumors, the addition of the checkpoint inhibitor atezolizumab to standard chemotherapy significantly impr...

The ASCO Post

June 13, 2025

FDA Approves Immune Checkpoint Inhibitor Drug for Patients With Resectable Locally Advanced Head and Neck Cancer

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) ?1] as determined by an FDA-approved test.

Dana-Farber

May 06, 2025

Mammograms: The Experts Share Their Thoughts

In 2025, approximately 375,000 cases of breast cancer are expected to be diagnosed in the U.S., according to the American Cancer Society.

Baptist Health South Florida